Table 1.
Characteristics of study participants.
Table 2.
Identification of metabolites that were significantly differentiating plasma profiles of AAA patients from controls.
Table 3.
Identification of acylcarnitines that were significantly differentiating plasma profiles of AAA patients from controls.
Table 4.
Identification of lysophospholipids that were significantly differentiating plasma profiles of AAA patients from controls.
Figure 1.
PLS-DA plot of plasma metabolic profiles obtained for patients and controls with prediction for QCs.
▵ - small AAA, ▴ – large AAA, □ – control, + - Quality control Panel A shows PLS-DA model (R2 = 0.852, Q2 = 0.369) for all samples and all variables in three groups under investigation (A, S, and C). Panel B shows prediction for QC samples by the model obtained.
Figure 2.
PLS-DA plot of plasma metabolic profiles obtained for age matched aneurysm patients and controls.
▵ - small AAA, ▴ – large AAA, + - predicted AAA samples not matching in age Panel A shows PLS-DA model (R2 = 0.835, Q2 = 0.335) for plasma samples obtained from patients and controls matching in age (n = 11). Panel B shows prediction for additional samples of patients (4 with large and 4 with small AAA). Sample marked by the circle was obtained from the patient with AAA size of 5.4 cm, and was assigned to large AAA group because the patient was operated on.
Figure 3.
PLS-DA plot of plasma metabolic profiles obtained for age matched large aneurysm patients and controls.
▵ - small AAA, ▴ – large AAA, □ – control Panel A shows PLS-DA model (R2 = 0.977, Q2 = 0.817) for plasma samples obtained from patients with large AAA and controls matching in age (n = 11). Panel B shows prediction for all samples of small AAA patients.